Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

The following is a summary of “Unveiling the Prevalence and Impact of Silent Rhinovirus Infection in Chronic Rhinosinusitis with Nasal Polyps,” published in the January 2025 issue of Annals of Allergy ...

A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery among patients with CRSwNP.

CRSwNP, for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. It is estimated that about 107 million people in China suffer from chronic sinusitis ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...

Simultaneously, the three regulators are also reviewing a second potential indication for depemokimab as an add-on therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). GSK has said ...

Concerning CRSwNP, GSK intends to secure approval in adults. Similar regulatory filings for the drug have also been validated for review in China and Japan. If approved, depemokimab will be the ...

Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...

Similarly, the ANCHOR trials showed that depemokimab effectively reduced nasal polyp size and obstruction in CRSwNP patients compared to placebo. Depemokimab, a monoclonal antibody targeting ...

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing Submissions based on data from positive SWIFT and ANCHOR trials SWIFT-1 and -2 showed depemokimab reduced ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently undervalued according to InvestingPro Fair Value metrics, has reached a ...